| Description |
Colestilan (MCI-196) is a non-absorbed, non-calcium-based phosphate binder and is also a non-metallic, anion exchange resin. Colestilan is orally active and can be used for hypercholesterolaemia research[1][2].
|
| Related Catalog |
|
| In Vitro |
Colestilan (MCI-196) decreases cholesterol levels by bile acid adsorption through the gastrointestinal tract[2]. Colestilan (1 g) binds 2.52 mmol of phosphate at 2–4 mM phosphate concentration and pH7.2 in vitro[2].
|
| In Vivo |
Colestilan (MCI-196) (0.125 or 0.5 g content per 15 g of the feed; p.o.; 14 days) decreases blood phosphate and urinary phosphorus excretion in rats[3]. Colestilan is able to improve hyperphosphataemia in rats with renal failure induced by adenine administration for 4 weeks[1]. Animal Model: 6-week old Wistar male rats[3] Dosage: 0.125 or 0.5 g content per 15 g of the feed Administration: Oral in feed, 14 days Result: Dose dependently decreased blood phosphate and urinary phosphate excretion.
|
| References |
[1]. Locatelli F, et al. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant. 2010 Feb;25(2):574-81. [2]. Kurihara S, et al. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplant. 2005 Feb;20(2):424-30. [3]. MATSUKA MASAYUKI, et al. Use of anion exchange resins for the manufacture of a medicament for the treatment of hyperphosphatemia. Patent EP0793960.
|
